Reported Earnings • 2h
Second quarter 2026 earnings released: US$0.005 loss per share (vs US$0.011 loss in 2Q 2025) Second quarter 2026 results: US$0.005 loss per share (improved from US$0.011 loss in 2Q 2025). Net loss: US$8.89m (loss narrowed 44% from 2Q 2025). Revenue is forecast to grow 193% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Jul 09
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma Northwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls. Announcement • Apr 01
Northwest Biotherapeutics, Inc. announced delayed annual 10-K filing On 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Nov 20
Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025 Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United States Reported Earnings • Nov 17
Third quarter 2025 earnings released: US$0.018 loss per share (vs US$0.015 loss in 3Q 2024) Third quarter 2025 results: US$0.018 loss per share (further deteriorated from US$0.015 loss in 3Q 2024). Net loss: US$26.5m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Announcement • Aug 28
Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings.
The transaction is expected to close as soon as certain legal conditions are fulfilled. Announcement • Aug 19
Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman Northwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time. Reported Earnings • Aug 15
Second quarter 2025 earnings released: US$0.01 loss per share (vs US$0.015 loss in 2Q 2024) Second quarter 2025 results: US$0.01 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$14.8m (loss narrowed 19% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Announcement • Jul 02
Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 17,727,273
Price\Range: $0.22 Announcement • Jun 12
Northwest Biotherapeutics Announces Upcoming Presentation on Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments Northwest Biotherapeutics announced that Dr. Marnix Bosch, its Chief Technical Officer, will make a presentation on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses" at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. Dr. Bosch will address certain factors and combinations of factors that may lead to supercharged dendritic cells with enhanced anti-tumor effects. The presentation will take place on June 16, at 2:50 p.m. The slides will be posted on the company's website after the presentation. Reported Earnings • May 16
First quarter 2025 earnings released: US$0.014 loss per share (vs US$0.016 loss in 1Q 2024) First quarter 2025 results: US$0.014 loss per share. Net loss: US$19.3m (loss widened 2.5% from 1Q 2024). New Risk • Apr 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$58m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-US$79m). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (US$1.4m revenue). Reported Earnings • Apr 01
Full year 2024 earnings released: US$0.067 loss per share (vs US$0.058 loss in FY 2023) Full year 2024 results: US$0.067 loss per share (further deteriorated from US$0.058 loss in FY 2023). Net loss: US$83.8m (loss widened 30% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Announcement • Dec 27
Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million. Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 21,587,302
Price\Range: $0.255
Discount Per Security: $0.019125
Transaction Features: Registered Direct Offering Reported Earnings • Nov 14
Third quarter 2024 earnings released: US$0.015 loss per share (vs US$0.017 loss in 3Q 2023) Third quarter 2024 results: US$0.015 loss per share. Net loss: US$19.5m (loss widened 2.1% from 3Q 2023). Reported Earnings • Aug 11
Second quarter 2024 earnings released: US$0.014 loss per share (vs US$0.014 loss in 2Q 2023) Second quarter 2024 results: US$0.014 loss per share (in line with 2Q 2023). Net loss: US$17.4m (loss widened 16% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • May 25
Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024 Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024. Location: offices of gibson, dunn & crutcher llp, 1050 connecticut avenue nw, washington, dc 20036, United States Announcement • Mar 22
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors Northwest Biotherapeutics announced that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski's term as an independent director, following Mr. Jasinowski's retirement due to health reasons as previously reported. Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees. Mr. Sarma is a longtime shareholder of NWBio. In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor. One of the companies he founded and built was American Megatrends Inc. (AMI), which became a major player in hardware, software and firmware components of PC-based systems. The company was known for developing the AMIBIOS firmware program for IBM-PC compatibility. The BIOS (Basic Input Output System) is the heart of PC-compatibility and all application programs access the BIOS in reading from or writing to peripheral units such as drives, keyboards, mouse. Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets. He was an owner for a number of years of the N.J. Devils team in the National Hockey League, and has invested in a diverse range of industries including medical and environmental companies. Mr. Sarma has been an investor in NWBio for more than a decade. Mr. Sarma received a Master's Degree in Industrial Engineering and Operations Research from Georgia Tech and a Bachelor's Degree in Mechanical Engineering from the University of Madras. Announcement • Mar 03
Northwest Biotherapeutics, Inc. announced delayed annual 10-K filing On 03/01/2024, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Dec 22
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma Northwest Biotherapeutics announced that a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®?-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. GBM is the most lethal and most common form of primary brain cancer. Despite well over 400 clinical trials of a wide range of treatment agents, patient survival in newly diagnosed GBM is only 15-17 months and has not meaningful improved in 20 years; survival in recurrent GBM is only 6-8 months and has not improved in 30 years. The Company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM in patients treated with DCVax-L compared with independently selected, matched, contemporaneous, pre-specified external controls. The trial also demonstrated more than doubling of the percentage of patients alive at 5 years in newly diagnosed GBM, and more than doubling of patients alive at 3 years after tumor recurrence in recurrent GBM patients, although the numbers of patients available for comparison at late time points was small, especially in the external control populations. One of the key factors making GBM so difficult to treat is that it is an extremely heterogeneous tumor. DCVax-Direct involves essentially the same mechanism of action as DCVax-L, except that the tumor target proteins are taken up by the dendritic cells in situ in the tumor following intra-tumoral injection, rather than from tumor lysate from a surgically resected tumor tissue sample. The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors. For the GBM MAA, the Company anticipates that the review process will be a period of intensive and extensive further work involving responding to questions and requests for further information by the regulatory authority as well as preparing for and undergoing detailed inspections of the contract research organizations (CROs) that managed the trial, the Sponsor, the Trial Master File, a number of individual trial sites selected by the regulatory from among the 94 sites that participated in the trial, the GMP facility and manufacturing information. Reported Earnings • Nov 12
Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.032 loss in 3Q 2022) Third quarter 2023 results: US$0.016 loss per share (improved from US$0.032 loss in 3Q 2022). Net loss: US$18.6m (loss narrowed 43% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Sep 13
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board Northwest Biotherapeutics announced that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine. The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing. Reported Earnings • Aug 10
Second quarter 2023 earnings released: US$0.014 loss per share (vs US$0.03 loss in 2Q 2022) Second quarter 2023 results: US$0.014 loss per share (improved from US$0.03 loss in 2Q 2022). Net loss: US$15.0m (loss narrowed 50% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 12
First quarter 2023 earnings released: US$0.01 loss per share (vs US$0.015 loss in 1Q 2022) First quarter 2023 results: US$0.01 loss per share (improved from US$0.015 loss in 1Q 2022). Net loss: US$11.0m (loss narrowed 22% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 02
Full year 2022 earnings released: US$0.10 loss per share (vs US$0.20 profit in FY 2021) Full year 2022 results: US$0.10 loss per share (down from US$0.20 profit in FY 2021). Net loss: US$105.0m (down 159% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Dec 06
Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 30, 2022 Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 30, 2022, at 13:30 Eastern Standard Time. Location: Gibson, Dunn & Crutcher LLP, 1050 Connecticut Avenue NW Washington, DC District Of Columbia United States Agenda: To elect two members to Board of Directors to serve as Class III Directors for a term of three years; to ratify the appointment of Cherry Bekaert LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to ratify the same stock option awards that were made to the company’s executive officers in 2020 and for which the stockholders already voted in favor in an advisory vote by stockholders at last year’s 2021 Annual Meeting; and to discuss other matters. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 43% share price gain to €1.26, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 570% over the past three years. Announcement • Nov 18
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma Northwest Biotherapeutics reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial. The Company believes this is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma.Glioblastoma is the most common and most lethal form of primary brain cancer. Standard of care (SOC) treatments have been virtually unchanged for nearly 20 years. With SOC treatments, patients typically survive for only about 15-17 months from diagnosis, with the tumor recurring at about 6-8 months from diagnosis and the patients typically surviving for about 7-9 months after recurrence. Five-year survival from diagnosis is only about 5%. In the Phase III trial of DCVax®-L, median Overall Survival (mOS) for newly diagnosed GBM patients (n=232) was 19.3 months from randomization (22.4 months from surgery) with DCVax-L vs. 16.5 months from randomization in the controls (HR=0.80, p=0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For recurrent GBM (n=64), mOS was 13.2 months from relapse vs. 7.8 months (HR = 0.58, p<0.001). Survival at 24 and 30 months post-recurrence was 20.7% vs. 9.6%, and 11.1% vs 5.1%, respectively. In newly diagnosed GBM patients with methylated MGMT, mOS was 30.2 months from randomization (33 months from surgery) with DCVax-L (n=90) vs. 21.3 months in controls (n=199) (HR=0.74, p=0.027). From a safety perspective, out of more than 2,100 doses of DCVax-L administered during the Phase III trial, there were only 5 serious adverse events that were deemed at least possibly related to the treatment. There were 3 cases of intracranial edema, 1 case of nausea and 1 case of lymph node infection. DCVax-L is a fully personalized immune therapy made from a patient's own immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's own tumor. A multi-year set of doses is produced in a single manufacturing batch, which takes 8 days. The product is then stored frozen in individual doses, and is "off the shelf" throughout the treatment regimen. The doses are stored centrally and simply taken out of the freezer and delivered to the physician when needed for the patient's next treatment. The Company is currently working on preparations for applications for regulatory approval of DCVax®-L. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 9 highly experienced directors. Independent Director J. Black was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 11
Third quarter 2022 earnings released: US$0.032 loss per share (vs US$0.052 profit in 3Q 2021) Third quarter 2022 results: US$0.032 loss per share (down from US$0.052 profit in 3Q 2021). Net loss: US$32.9m (down 172% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 24
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA Northwest Biotherapeutics announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the Company's Pediatric Investigation Plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for adult patients, such as DCVax®-L. The Company's approved PIP includes 2 clinical trials: one for newly diagnosed pediatric high grade glioma (HGG), and one for recurrent pediatric HGG. In each of the 2 pediatric trials, 24 patients will be treated with DCVax-L on the same treatment schedule as in the Company's Phase III trial in adult glioblastoma patients. The primary endpoint for each of the 2 pediatric trials will be overall survival, determined by comparing the survival of DCVax-L treated patients to matched contemporaneous external controls. The external controls will be identified using the same methodology as was used to pre-specify the external controls in the Statistical Analysis Plan for the Company's Phase III trial in adult patients. Under applicable UK law, when a new medicine is developed for adult patients, that medicine must also be tested for potential application to pediatric patients. The sponsor must develop an overall Plan to select the specific form or stage of the disease to be treated, to adapt the dosing and administration of the medicine for pediatric physiology, and to evaluate the safety and efficacy of the medicine in pediatric patients. Further, the Plan must include not just general focus areas, aims and approaches -- it must include the full design of the specific clinical trials to be carried out, including all aspects required for clinical trial approvals, such as the patient population, eligibility criteria, stage of disease, treatment regimen, trial design and endpoints. The Plan developed by the sponsor must go through a series of stages of regulatory review and comment to reach a final approval by regulators. This process can typically take more than a year.The final regulatory approval of the PIP must be obtained before a sponsor may submit a Marketing Authorization Application (MAA) for approval to commercialize the new medicine for adult patients. The approval may include a deferral allowing the pediatric clinical trials to actually be carried out after the MAA has been submitted, but the PIP approval itself must have been received before an MAA can be filed and go through compliance check. Reported Earnings • Aug 11
Second quarter 2022 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2021) Second quarter 2022 results: US$0.03 loss per share (down from US$0.005 profit in 2Q 2021). Net loss: US$29.7m (down US$34.1m from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 11
First quarter 2022 earnings released: US$0.015 loss per share (vs US$0.005 loss in 1Q 2021) First quarter 2022 results: US$0.015 loss per share (down from US$0.005 loss in 1Q 2021). Net loss: US$14.2m (loss widened 245% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improved over the past week After last week's 40% share price gain to €1.19, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 34x in the Biotechs industry in Europe. Total returns to shareholders of 345% over the past three years. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 9 highly experienced directors. Independent Director J. Black was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Mar 04
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: US$0.20 (up from US$0.73 loss in FY 2020). Net income: US$179.1m (up US$708.9m from FY 2020). Revenue missed analyst estimates by 12%. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings. Announcement • Dec 22
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility Northwest Biotherapeutics announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility. The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the smaller GMP facility in London. The license also permits the import and GMP manufacture of other cell therapy products under the UK's supply of unlicensed medicinal products ('Specials') regime and for clinical trials under the Investigational Medicinal Products (IMP) Programme. The Company is developing the Sawston facility in phases, both to optimize the timing of capital requirements and to enable each phase to be when developed, as manufacturing technologies are advancing significantly in the field of cell therapies. To date, the Company has developed Phase 1A of the facility, comprising approximately 4,400 square feet of the overall 88,345 square feet. The Company anticipates that Phase 1A alone will be able to manufacture DCVax-L products for 45-50 patients per month, or 450-500 patients per year – a significant increase from the current manufacturing capacity of four to six patients per month which, to date, has been taking place in a GMP clean room facility in London, UK. This MHRA license is a culmination of intensive preparations that have been underway for much of 2021. The process included an extensive application process, a week-long inspection of all aspects of the physical facility, its construction and equipment, all aspects of the facility's operations, including all operating systems, flow of materials and activities, sterility, quality control, staff and other factors, and all of the regulatory documentation, including standard operating procedures (SOPs) for the facility and for the product, batch manufacturing records, data from practice manufacturing runs and other required documents. This MHRA license follows the license approval by the UK'sHuman Tissue Authority (HTA) in October. That license covers the collection, processing and storage of human tissue and cells for medical purposes, including cell therapies such as DCVax-L. The preparatory work and applications for the MHRA and HTA licenses have been carried out by Advent Bioservices, NWBio's UK entity contract manufacturer, operator, and license holder. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS US$0.052 (vs US$0.26 loss in 3Q 2020) Third quarter 2021 results: Net income: US$45.5m (up US$239.6m from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 126 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS US$0.005 (vs US$0.083 loss in 2Q 2020) Second quarter 2021 results: Net income: US$4.41m (up US$62.4m from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance. Reported Earnings • May 19
First quarter 2021 earnings released: US$0.005 loss per share (vs US$0.005 profit in 1Q 2020) First quarter 2021 results: Net loss: US$4.12m (down 242% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 108% per year, which means it is well ahead of earnings. Announcement • May 13
Northwest Biotherapeutics Announces UK Manufacturing Facility & Phase III Trial Updates Northwest Biotherapeutics announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial. On May 7, the application package was submitted to the MHRA requesting the certification of the Sawston facility to produce Good Manufacturing Practice (GMP) clinical grade medical products for patients. This application represents the culmination of more than 2 years of preparations, including more than a year conducting these efforts under challenging COVID-19 restrictions and conditions. As previously reported on March 16, 2021, the preparations have included the physical buildout of Phase I of the facility, development of over 500 regulatory documents (including Standard Operating Procedures (SOPs) for all aspects of operations, batch manufacturing records, and other formal documents), development of a Sawston team of nearly 40 persons with all of the required types of expertise for production of Advanced Therapy Medicinal Products (ATMPs) and training in regard to the DCVax® technology and processes. The next step will be an on-site inspection of the facility by MHRA. Following the inspection, a report of the inspection results and any findings needing any corrective action will be issued by MHRA. Following completion of any actions, the Company is hopeful that an initial license will be issued and production of GMP DCVax-L products in the Sawston facility may begin by around the end of Q3. In addition to the MHRA submission activities, a prototype of the Flaskworks system has been delivered to the Sawston facility, and the Company currently anticipates that initial practice runs with the system may begin at the Sawston facility during the summer. Meanwhile, manufacturing of vaccine products for compassionate use patients ("Specials") has been and is continuing at the GMP facility in London. The process outlined in the Company's October 5, 2020 announcement relating to the Phase III trial of DCVax-L is continuing to move forward. The process includes review and analysis of the raw data by independent statisticians and experts, and preparation of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts in preparation for public announcement and scientific publication. The Company continues to be in a quiet period while this process is under way. The Company appreciates shareholders' patience, and their understanding that the Company cannot make partial disclosures during this process and cannot comment on the Phase III trial schedule or its data until the announcement of the results. Reported Earnings • Apr 02
Full year 2020 earnings released: US$0.73 loss per share (vs US$0.036 loss in FY 2019) Full year 2020 results: Net loss: US$529.8m (loss widened US$509.5m from FY 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 72% per year, which means it is well ahead of earnings. Announcement • Nov 11
Northwest Biotherapeutics, Inc. announced delayed 10-Q filing On 11/10/2020, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Oct 14
Northwest Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $9.97557 million. Northwest Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $9.97557 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 12,224,963
Price\Range: $0.816 Is New 90 Day High Low • Oct 12
New 90-day high: €0.92 The company is up 176% from its price of €0.33 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period. Announcement • Oct 06
Northwest Biotherapeutics Announces Data Lock of Phase III Trial Northwest Biotherapeutics announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage. The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication. Is New 90 Day High Low • Sep 19
New 90-day high: €0.79 The company is up 148% from its price of €0.32 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. Announcement • Sep 02
Northwest Biotherapeutics, Inc. (OTCPK:NWBO) acquired Flaskworks, LLC for $4.3 million. Northwest Biotherapeutics, Inc. (OTCPK:NWBO) acquired Flaskworks, LLC for $4.3 million on August 28, 2020. The acquisition includes both intellectual property owned by Flaskworks and a license of additional intellectual property from Northeastern University. The total purchase price was approximately $4.33 million, of which $1.65 million was paid in cash at closing, up to $2.01 million will be paid in stock subject to milestone-based vesting, and $0.67 million will be paid in either cash or stock, or a combination thereof, within 120 days after the closing. The technical team from Flaskworks will join Northwest Biotherapeutics as part of the transaction.
Northwest Biotherapeutics, Inc. (OTCPK:NWBO) completed the acquisition of Flaskworks, LLC on August 28, 2020. Announcement • Aug 21
Northwest Biotherapeutics, Inc. announced that it has received $5.005 million in funding from Iliad Management, LLC Northwest Biotherapeutics, Inc. (NasdaqCM:NWBO) announced that it has entered into a note purchase agreement with Iliad Research and Trading, L.P., a fund managed by Iliad Management, LLC for private placement of a non convertible promissory note for gross proceeds of $5,005,000 on August 14, 2020. The note carries a fixed coupon of 8% per annum. The note have a 21 months maturity. There are no repayments during the first 7 months of the note and during months 8 through 21, the note will be amortized in monthly installments of 110% of the pro-rata principal amount. The notes are issued at an original issue discount of $500,000. The note contains customary default provisions, including provisions for potential acceleration of the note and default interest. 
